Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 8/20 | 0.50 |
| ▸ | CA1 | P00915 | 8/20 | 0.48 |
| ▸ | CA2 | P00918 | 8/20 | 0.48 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CA6 | P23280 | 4/20 | 0.48 |
| ▸ | CA5A | P35218 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.48 |
| ▸ | CA3 | P07451 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1942774 | 0.83 | CA1 (0.48) | PTGES2CA1CA2CA12CA9 | |
| SCHEMBL1060711 | 0.81 | TRPV4 (0.44) | PTGES2 | |
| SCHEMBL941568 | 0.79 | MMP2 (0.64) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2127269 | 0.78 | CA1 (0.53) | PTGES2CA1CA2CA12CA9 | |
| SCHEMBL29852349 | 0.78 | CA1 (0.53) | PTGES2CA1CA2CA12CA9 | |
| SCHEMBL1127112 | 0.78 | PTGES2 (0.49) | PTGES2CA1CA2CA12CA9 | |
| SCHEMBL29721599 | 0.78 | PTGES2 (0.49) | PTGES2CA1CA2CA12CA9 | |
| SCHEMBL939746 | 0.78 | CISD1 (0.41) | CA1CA2CA12CA9CA4 | |
| Hydrochloric Acid SCHEMBL28163878 | 0.78 | KMT2A (0.40) | PTGES2POLB | |
| SCHEMBL10838459 | 0.77 | CA9 (0.46) | PTGES2CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| CN-111526877-B | Compounds and compositions for IRE1 inhibition | 奥普提卡拉公司 | 2023-08-25 | — | — | CN | claimed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | disclosed |
| CN-111526877-B | Compounds and compositions for IRE1 inhibition | 奥普提卡拉公司 | 2023-08-25 | — | — | CN | disclosed |
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-06-11 | — | — | US | disclosed |
| EP-3372583-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-09-12 | — | — | EP | disclosed |
| US-20180251448-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-09-06 | — | — | US | disclosed |
| CN-108349894-A | The method for removing dimethoxy-benzyl | 第三共株式会社 | 2018-07-31 | — | — | CN | disclosed |
| EP-2838519-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN (IE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2838519-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN (IE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | ATXA THERAPEUTICS LIMITED (IE) | 2017-10-19 | — | — | US | disclosed |
| US-20160016900-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016900-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016900-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2016-01-21 | — | — | US | disclosed |
| EP-2838520-A2 | THROMBOXANE RECEPTOR ANTAGONISTS | University College Dublin National University Of Ireland, Dublin (IE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2838519-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | University College Dublin National University Of Ireland, Dublin (IE) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013156871-A9 | THROMBOXANE RECEPTOR ANTAGONISTS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-01-08 | — | — | WO | disclosed |
| WO-2013156871-A9 | THROMBOXANE RECEPTOR ANTAGONISTS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-01-08 | — | — | WO | disclosed |
| WO-2013156861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013156871-A2 | THROMBOXANE RECEPTOR ANTAGONISTS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251448-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DDT, ALKBH5, DDO | PTGES2 3385/4885CA1 2756/4885CA2 3283/4885 |
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | TBXA2R, PTGFR, TBXAS1 | PTGES2 155/4885CA1 4728/4885CA2 3111/4885 |
| US-20160016900-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | TBXA2R, TBXAS1, PTGIR | PTGES2 99/4885CA1 4340/4885CA2 2497/4885 |
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DDT, ALKBH5, DDO | PTGES2 3385/4885CA1 2756/4885CA2 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.